Company Overview
Perennial Holdings is an integrated real estate and healthcare company headquartered in Singapore, with operations spanning China, Singapore, Malaysia, and Ghana. China remains its core market, supported by healthcare and eldercare platforms concentrated in key cities such as Kunming, Chengdu, Guangzhou, and Xi’an. The group operates under a hybrid model that combines property ownership, development, and healthcare operations. Its shareholder base includes Kuok Khoon Hong (29%), Wilmar International (16%), Hopu Investments (14%), Perpetual Capital (11%), Ron Sim (13%), Bangkok Bank (9%), and Pua Seck Guan (8%).
1H2025 Performance
Perennial’s operating momentum continues to strengthen as its healthcare and eldercare platforms gain scale. Portfolio occupancy has risen to 65% as of YTD 2025 (from 51% in 2022), while mature assets have reached a robust 86% occupancy, underscoring strong utilisation once stabilised. Earnings reflect this ramp-up, with adjusted EBITDA at S$223.6 million in FY2024 and S$13.5 million in 1H2025, marking a solid 65% YoY growth. Importantly, the business has shifted structurally toward recurring income, with over 55% of revenue now driven by healthcare operations. Further scalability is supported by a 4,500-bed brownfield pipeline across Guangzhou, Chengdu, Shanghai, and Hainan (launching 4Q2026–4Q2027) and the upcoming Kunming Medical City in 1Q2026, which will anchor recurring EBITDA growth over the medium term.
Despite improving operations, the credit profile remains constrained by elevated leverage and tight interest coverage. Debt/Total Assets has risen to 0.41× (from 0.38×), while Net Debt/Equity has increased to 0.83× (from 0.71×), reflecting ongoing project investment and slower capital recycling. Though the adjusted ICR of ~1.0× better captures cash-servicing ability compared to the reported 0.15×, both measures highlight thin headroom amid funding- cost volatility. Refinancing execution has been constructive—with ~86% of unsecured facilities rolled over and all secured loans under renewal—but the schedule remains front-loaded, keeping liquidity dependent on timely renewals and selective asset monetisation. A diverse lending syndicate (DBS, UOB, OCBC, Maybank, BBL, SMBC, ICBC, BoC) helps mitigate concentration risk.
Looking ahead, several milestones will be key to shaping Perennial’s credit trajectory. The ramp-up in occupancy and EBITDA following the launch of Kunming Medical City in 1Q2026 will be crucial in lifting the adjusted ICR toward a more sustainable level above 1.5×. Liquidity conditions also hinge on the timely completion of remaining unsecured renewals and the ability to secure longer tenors beyond the typical three-year cycle. In addition, refinancing spreads will need close monitoring, as Perennial’s thin coverage base leaves the credit profile sensitive to funding-cost volatility.
Credit View: Perennial’s credit profile has shown gradual improvement, underpinned by better operating momentum and clearer visibility on recurring healthcare earnings. However, leverage remains high and ICR tight amid a front-loaded refinancing schedule. We stay cautiously constructive, recognising improving fundamentals but noting continued reliance on refinancing and capital recycling.
Overview of Perennial Holdings’ Outstanding SGD Bonds
Disclaimer
These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.
Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.
Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.
The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.
Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.
